Refine by
Patient Support Articles & Analysis
98 news found
Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for all solid tumor cancers as an ...
ByTempus
We are thrilled to welcome KEMP Hospice to the growing community of amazing charities we work with across the UK. We are proud to provide the charity with our affordable and adaptable software solutions that support the outstanding care they provide to families and people living with life-limiting illnesses across their ...
We are delighted to welcome Saint Catherine’s Hospice Scarborough to the growing community of amazing hospice charities we work with across the UK. We are proud to provide Saint Catherine’s with our affordable and adaptable software solutions that support the outstanding care they provide to people with life-limiting ...
We are delighted to welcome St Luke’s Hospice to the growing community of amazing hospice charities we work with across the UK. We are proud to provide St Luke’s with our affordable and adaptable software solutions that support the outstanding care they provide to people living with life-limiting illnesses. ...
“These clinically important results show that the burden of disease can be reduced for many more patients in the future contributing to improved adherence and thus better patient outcomes.” “Diabetic macular edema is a leading cause of vision loss, and we are fully committed to support patients with extended ...
ByBayer AG
Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has installed additional Nuclear Magnetic Resonance (NMR) equipment which will double Lifespin’s annual laboratory testing capacity. Lifespin will now be able to scan and create the corresponding digitized, quantitative metabolic profiles involving as many as 300,000 human samples ...
Dr. Ali Tinazli's post at the Forbes magazine about "History Of Health Technologies And Meaningful Change In The Era Of Health 4.0" The medicine in ancient Egypt is some of the oldest in history. Although rudimentary, it was already highly personalized and with exclusive access. During the Renaissance—one of the most remarkable ages of humankind—medicine ...
Treatment-emergent AEs led to dose reductions in 16 patients (31.4%) and to dose interruptions in 33 patients (64.7%). Seven patients (13.7%) discontinued treatment due to AEs. ...
Stemline ARC, a patient support program is available to help guide eligible patients through the various aspects of getting started on treatment, from providing educational information to helping them understand their insurance coverage and identifying potential financial assistance options. For more information, patients and ...
“With limited access to novel agents in these markets and with large populations, a high unmet medical need exists in management of both patients with MM and DLBCL. When approved, XPOVIO® will offer an important novel treatment option in the care of patients with these life threatening diseases in Macau,China, Malaysia and ...
“We look forward to Amit’s leadership and insights, generated from his deep experience across many sectors of healthcare, spanning both patient-centric and clinician-facing digital health chronic disease ...
Cirdan are delighted to announce that together with Queen’s University Belfast and our KTP Associate and Senior AI Engineer, Jonathan Armstrong, we have been selected as the winners of the Best KTP project by Innovate UK. Innovate UK’s Best Knowledge Transfer Partnership award honours the KTP which has brought the greatest benefits to all three participants, exceeding the expectations ...
Toro Equipment supports the 22q11 Syndrome Association, a non-profit organisation that aims to be a link between families, professionals and organisations involved in the care of people with 22q11 deletion and 22q11 duplication, in order to improve their quality of life and social integration. ...
“Together with xCures and Faeth Therapeutics, we are looking forward to rapidly recruiting and enrolling patients where they are, reducing recruitment timelines and costs, and increasing patient ...
ByxCures
Providers have been able to gauge which patients are stable enough for take-homes, and also to trust the patients and earn trust in return. ...
Timberlake continued, "Prior to the COVID-19 epidemic, there was a serious unmet need to support OUD patients. Now there is an even greater critical need for a system capable of accurately and securely dispensing methadone for at home use that incorporates real-time remote monitoring, as the pandemic has limited access to methadone maintenance treatment (MMT) ...
FDA Orphan Drug Designation reflects urgent need for new therapies for glioblastoma (GBM) patients Next steps for development of VBI-1901 : Q3 2022: Expected initiation of randomized, controlled clinical study in recurrent GBM patients with potential to support accelerated approval application Q4 2022: Expected initiation of randomized, ...
Led by the Netherlands-based Oncode Institute, the consortium will be supported by the National Growth Fund, an initiative of the Dutch Ministry of Economic Affairs and Climate Policy and the Ministry of Finance. ...
PatientPoint today announced that it will be supporting the Susan G. Komen®Stand for H.E.R—a Health Equity Revolution program by bringing point-of-care breast health resources to patients and healthcare providers in U.S. metropolitan areas where breast cancer mortality gaps are greatest between Black and white women. ...
Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that breast cancer oncologist Daniel F. ...